{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:25:21Z","timestamp":1775687121702,"version":"3.50.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T00:00:00Z","timestamp":1555632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Takeda Pharmaceuticals International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>We previously reported the tolerability and immunogenicity 1 month after intramuscular administration of 2 bivalent virus-like particle (VLP)\u2013based candidate norovirus vaccine formulations in adults. We now describe the persistence of immunity and responses to a memory probe vaccination 1 year later.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 454 healthy men and women aged 18\u201349 years in 3 equal groups received placebo (saline) or 15\/50 or 50\/50 vaccine formulations (ie, 15 or 50 \u00b5g of GI.1 genotype VLPs, respectively, and 50 \u00b5g of GII.4c VLPs) with MPL and Al(OH)3. Immunogenicity and safety were assessed up to day 365, when 351 participants received a memory probe vaccination of 15 \u00b5g each of GI.1 and GII.4c VLPs with Al(OH)3.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No safety signals were detected up to 1 year after the first vaccination. Pan-immunoglobulin, immunoglobulin A, and histo-blood group antigen\u2013blocking (HBGA) antibody levels among vaccinees waned but remained higher than levels before vaccination and levels in placebo recipients on days 180 and 365. Memory probe vaccination increased all antibody titers. Levels of HBGA antibodies to GI.1 but not GII.4c were higher after the first vaccination in candidate vaccine groups, compared with those in the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Levels of antibodies to both candidate norovirus VLP formulations persisted above baseline levels for at least 1 year after primary vaccination. HBGA-blocking responses to the memory probe for GI.1 but not GII.4c displayed characteristics of immune memory.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trials Registration<\/jats:title><jats:p>NCT02142504.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiz170","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T19:19:31Z","timestamp":1554837571000},"page":"603-614","source":"Crossref","is-referenced-by-count":29,"title":["Persistence of Antibodies to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: 1-Year Follow-up With Memory Probe Vaccination"],"prefix":"10.1093","volume":"220","author":[{"given":"Robert L","family":"Atmar","sequence":"first","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Baehner","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob P","family":"Cramer","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lloyd","sequence":"additional","affiliation":[{"name":"Takeda Vaccines, Deerfield, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Sherwood","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Borkowski","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M","family":"Mendelman","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"NOR-201 Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S","family":"Al-Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald M","family":"Brandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew G","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey B","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Treanor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,4,19]]},"reference":[{"key":"2019071901595856200_CIT0001","volume-title":"WHO estimates of the global burden of foodborne diseases","author":"Foodborne Disease Burden Epidemiology Reference Group 2007\u20132015"},{"key":"2019071901595856200_CIT0002","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1086\/657133","article-title":"High level of gastrointestinal nosocomial infections in the German surveillance system, 2002-2008","volume":"31","author":"Spackova","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2019071901595856200_CIT0003","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/infdis\/119.6.668","article-title":"Winter vomiting disease","volume":"119","author":"Adler","year":"1969","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0004","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1469-0691.2005.01299.x","article-title":"Risk groups for clinical complications of norovirus infections: an outbreak investigation","volume":"12","author":"Mattner","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"2019071901595856200_CIT0005","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ajic.2012.08.002","article-title":"Clinical characteristics of norovirus-associated deaths: a systematic literature review","volume":"41","author":"Trivedi","year":"2013","journal-title":"Am J Infect Control"},{"key":"2019071901595856200_CIT0006","doi-asserted-by":"crossref","first-page":"e0151219","DOI":"10.1371\/journal.pone.0151219","article-title":"Global economic burden of norovirus gastroenteritis","volume":"11","author":"Bartsch","year":"2016","journal-title":"PLoS One"},{"key":"2019071901595856200_CIT0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4315\/0362-028X.JFP-11-460","article-title":"Persistence and transferability of noroviruses on and between common surfaces and foods","volume":"75","author":"Escudero","year":"2012","journal-title":"J Food Prot"},{"key":"2019071901595856200_CIT0008","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/AEM.01729-09","article-title":"Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands","volume":"76","author":"Liu","year":"2010","journal-title":"Appl Environ Microbiol"},{"key":"2019071901595856200_CIT0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jcv.2012.11.011","article-title":"Molecular epidemiology of noroviruses associated with acute sporadic gastroenteritis in children: global distribution of genogroups, genotypes and GII.4 variants","volume":"56","author":"Hoa Tran","year":"2013","journal-title":"J Clin Virol"},{"key":"2019071901595856200_CIT0010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/1469-0691.12746","article-title":"Evolution of norovirus","volume":"20","author":"White","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2019071901595856200_CIT0011","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.3201\/eid2107.150226","article-title":"Gastroenteritis outbreaks caused by norovirus GII.17, Guangdong Province, China, 2014-2015","volume":"21","author":"Lu","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2019071901595856200_CIT0012","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N Engl J Med"},{"key":"2019071901595856200_CIT0013","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/infdis\/jiu497","article-title":"Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults","volume":"211","author":"Bernstein","year":"2015","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0014","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/infdis\/jiu337","article-title":"A novel intramuscular bivalent norovirus virus-like particle vaccine candidate\u2013reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults","volume":"210","author":"Treanor","year":"2014","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1093\/infdis\/jiw259","article-title":"Rapid responses to 2 virus-like particle norovirus vaccine candidate formulations in healthy adults: a randomized controlled trial","volume":"214","author":"Atmar","year":"2016","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0016","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/infdis\/jix572","article-title":"Safety and immunogenicity of different formulations of norovirus vaccine candidate in healthy adults: a randomized, controlled, double-blind clinical trial","volume":"217","author":"Leroux-Roels","year":"2018","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0017","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1128\/JCM.31.4.1022-1025.1993","article-title":"Prevalence of antibodies to Norwalk virus in England: detection by enzyme-linked immunosorbent assay using baculovirus-expressed Norwalk virus capsid antigen","volume":"31","author":"Gray","year":"1993","journal-title":"J Clin Microbiol"},{"key":"2019071901595856200_CIT0018","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/514949","article-title":"Seroprevalence of Norwalk virus and Mexico virus in Chilean individuals: assessment of independent risk factors for antibody acquisition","volume":"27","author":"O\u2019Ryan","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2019071901595856200_CIT0019","doi-asserted-by":"crossref","first-page":"e1001807","DOI":"10.1371\/journal.pmed.1001807","article-title":"Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial","volume":"12","author":"Lindesmith","year":"2015","journal-title":"PLoS Med"},{"key":"2019071901595856200_CIT0020","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/CVI.00516-14","article-title":"Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity","volume":"22","author":"Czak\u00f3","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"2019071901595856200_CIT0021","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1086\/656364","article-title":"Serological correlate of protection against norovirus-induced gastroenteritis","volume":"202","author":"Reeck","year":"2010","journal-title":"J Infect Dis"},{"key":"2019071901595856200_CIT0022","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/CVI.00196-15","article-title":"Serological correlates of protection against a GII.4 norovirus","volume":"22","author":"Atmar","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"2019071901595856200_CIT0023","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/ana.410180308","article-title":"Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981","volume":"18","author":"Beghi","year":"1985","journal-title":"Ann Neurol"},{"key":"2019071901595856200_CIT0024","doi-asserted-by":"crossref","first-page":"e1001999","DOI":"10.1371\/journal.pmed.1001999","article-title":"The vast and varied global burden of norovirus: prospects for prevention and control","volume":"13","author":"Lopman","year":"2016","journal-title":"PLoS Med"},{"key":"2019071901595856200_CIT0025","doi-asserted-by":"crossref","first-page":"7097","DOI":"10.1016\/j.vaccine.2012.09.040","article-title":"The potential economic value of a human norovirus vaccine for the United States","volume":"30","author":"Bartsch","year":"2012","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz170\/28667791\/jiz170.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/4\/603\/28955686\/jiz170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T22:09:30Z","timestamp":1607206170000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/4\/603\/5475178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,19]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,19]]},"published-print":{"date-parts":[[2019,7,19]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz170","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,15]]},"published":{"date-parts":[[2019,4,19]]}}}